Eventide Gilead Fund

Class N (ETGLX)

Semi-Annual Shareholder Report - December 31, 2024



Fund Overview

This semi-annual shareholder report contains important information about Eventide Gilead Fund for the period of July 1, 2024 to December 31, 2024. You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836.

What were the Fund's costs for the last six months?


(based on a hypothetical \$10,000 investment)

Class Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Class N	\$72	1.40%*
		* Amuslicad

	Ailluailzed
	Fund Statistics
Net Assets	\$2,923,443,154
Number of Portfolio Holdings	85
Portfolio Turnover	38%

Top 10 Holdings* (% of net assets)		
Holding Name	% of Net Assets	
Xometry, Inc Class A	4.4%	
Trade Desk, Inc. (The) - Class A	3.4%	
Verona Pharma plc - ADR	3.0%	
Toast, Inc Class A	2.9%	
Global-e Online Ltd.	2.7%	
Guardant Health, Inc.	2.4%	
Trane Technologies PLC	2.4%	
Old Dominion Freight Line, Inc.	2.4%	
Monday.com Ltd.	2.3%	
Scholar Rock Holding Corporation	2.2%	

^{*} Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.



Where can I find additional information about the Fund?

Additional information is available on the Fund's website (https://www.eventidefunds.com), including its:



- Prospectus
- · Financial information
- Holdings
- · Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123124-ETGLX